GeneDx shares plunge 49% after huge Q1 loss and slashed 2026 revenue forecast

GeneDx Holdings Corp. shares dropped 49% on May 5, 2025, after the company reported a massive tenfold increase in net loss for Q1 2026 and cut its full-year 2026 revenue guidance by 12%. The company’s average reimbursement rate fell short due to a shift in product mix toward genome tests, which have lower reimbursement than exome tests. This unexpected downturn wiped out over $900 million in market value and triggered a shareholder rights investigation into possible securities law violations. Investors who suffered losses are encouraged to contact the investigating law firm, Hagens Berman, as the case develops.